The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
|Articles|February 1, 2003
Exploring Earth's Mysteries
Author(s)Karen Nash
There was little in his childhood in Washington, D.C., to indicate that Haines Ely's future would take him to a career as a dermatologist/dermatopathologist, with a weekly radio talk show that deals often in metaphysics and alternative medicines. He also leads trips to visit a faith healer in Brazil.
Advertisement
Advertisement
Related to this article
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
Topical vs Oral JAK Inhibitors for Vitiligo: How to Choose as Systemic Options Advance
4
Don't Be Rash: Balancing Topical Steroids in the Era of Nonsteroidals
5